Herbert Irving Assistant Professor of Medicine
New York, New York
My research goals are focused on developing targeted therapies for the treatment of lymphoma. As a physician-scientist, I aim to directly translate observations and concepts developed in the laboratory to patient care and back again to the laboratory. I have over 10 years of experience in directing laboratory procedures and experiments as well as clinical trial design, management, and recruitment. Specifically, I have concentrated on targeting epigenetic and transcriptional pathways in germinal-center derived diffuse large B-cell lymphoma (GC-DLBCL) and T-cell lymphomas with epigenetic drugs, alone and in combination with other agents. These projects all began at the bench for proof-of-principle investigation, and once established have all translated into investigator initiated early phase clinical trials. Taken together, my research focus is to develop personalized epigenetic treatment platforms for targeting a specific pathogenetic mechanism driving disease. The goal of these projects is to identify biomarkers for response to allow for treatment aimed at the biological drivers of disease regardless of cell of origin. Bridging ideas generated at the bench, these highly collaborative research projects, should allow for a strategic and rapid translation to clinical practice.